NCT05079230 2025-04-04
ENHANCE-3
Gilead Sciences
Phase 3 Terminated
Clinical Trials
6 trialsNCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT05367401 2024-04-11
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Novartis
Phase 1/2 Withdrawn
NCT05627466 2024-02-15
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Gilead Sciences
No longer available
NCT03922477 2022-02-21
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Hoffmann-La Roche
Phase 1 Terminated
NCT02678338 2019-02-21
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Gilead Sciences
Phase 1 Completed